trial summary · NCT07825857
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
Trial record from the TrialBase DB dataset, status RECRUITING, condition Methamphetamine Use Disorder, sponsored by University of Texas Southwestern Medical Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the tolerability, safety, and preliminary efficacy of tirzepatide for the treatment of individuals with moderate or severe methamphetamine use disorder (MtUD). The central hypothesis of the proposed research is that tirzepatide is a safe and potentially efficacious treatment of MtUD. Participants will undergo study procedures over 32 weeks, including: 1. completing self-assessments 2. undergo brief physical and review of medical and psychiatric history 3. provide urine and blood samples 4. medical management sessions 5. weekly subcutaneous study medication injections
Source record: https://clinicaltrials.gov/study/NCT07825857
Facts
| registry id | NCT07825857 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Methamphetamine Use Disorder |
| sponsor | University of Texas Southwestern Medical Center |
| sponsor class | OTHER |
| enrollment | 228 |
| start date | 2026-10-23 |
| primary completion | 2031-07-01 |
| completion | 2031-08 |
| results posted | not reported |
Conditions
- Methamphetamine Use Disorder
Interventions
- Tirzepatide
- Placebo (saline)
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.